Why the study?
Continuous subcutaneous insulin infusion systems improve glycemic control in diabetes but may have rare major complications.
Answers are grounded in this paper and cite their sources.
This is the first reported case of hemorrhagic shock due to a rectus abdominis hematoma at the infusion site of a continuous subcutaneous insulin pump.
Background: Continuous subcutaneous insulin infusion (CSII) systems, used to treat diabetes for over 40 years may improve glycemic control but also have rare major complications. Methods: We report the first hemorrhagic shock on the infusion site of an insulin pump, due to a rectus abdominis hematoma. Results: An eighty-one years old woman with history of cardiovascular events and type 1 diabetes, presented with hemorrhagic shock due to a rectus abdominis hematoma rapidly constituted at the insulin injection site. The situation improved after conservative treatment (blood transfusions, IV fluids, replacement of the CSII with insulin injections). Contributive factors to this complication were overdose of anticoagulant, oversized insulin canula and cough. Conclusion: We recommend increased monitoring of patients using insulin pump with hemorrhagic risk factors. Specific education for the prevention and detection of signs of hemorrhage should lead patients to report this situation promptly, in order to avoid this life-threatening complication.
No takes yet. Share an insight, caveat, or question.
Vaduva et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: